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Mx-Cre+ mice (CD45.2+) were transplanted with the equal number of competitor
cells (CD45.1+CD45.2+) into lethally irradiated CD45.1+ recipient mice. 4 weeks
after transplantation, pI-pC was administered to the recipient mice to delete
floxed alleles. The result showed that the percentage of Ogt-deleted cells was
remarkably decreased at 2 weeks after pI-pC injection and it progressively
decreased over time. These data suggest that Ogt is essential for competitive
and long-term repopulating capacity of BM-HSCs.
Summary and Conclusions: The O-GlcNAcylation by Ogt plays a critical role
for maintaining homeostasis of FL and BM hematopoiesis in mice.
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EXPLORING THE ROLE OF KIT LIGAND AT THE ONSET OF
HEMATOPOIESIS
E. Azzoni1, C. Nerlov1, M. De Bruijn*
1MRC Molecular Haematology Unit, Weatherall Instititute of Oxford, University
of Oxford, Oxford, United Kingdom
Background: Hematopoietic stem cells (HSCs) are generated during mam-
malian development from hemogenic endothelium in the major arteries through
a process called endothelial-to-hematopoietic transition. The extrinsic and intrin-
sic factors that orchestrate this process are poorly understood. Kit ligand (KitL;
also known as Stem Cell Factor/SCF) is a cytokine that plays a pivotal role in
the adult bone marrow HSC niche, and it is thought to act on several cell types
during embryogenesis. It is known that the absence of KitL causes a significant
reduction in the fetal liver HSC pool and leads to death in utero with severe
anaemia. However, it is currently unclear where, when and how the hematopoi-
etic defect originates in embryos lacking KitL, and what is the precise role of
this cytokine in the first steps of hematopoiesis.
Aims: Here we use a novel KitL transgenic reporter mouse line to map expres-
sion of this cytokine in the microenvironment of the Aorta-Gonad-Mesonephros
(AGM) and yolk sac hematopoietic sites in the developing embryo, and inves-
tigate the effect of loss of KitL in these pre-liver sites of hematopoiesis. 
Results: We show that KitL expressing cells are found in the microenvironment
of all hematopoietic sites of the E8.5-E10.5 mouse embryo. Loss of KitL as
assessed in Steel mutant (Sl/Sl) embryos showed smaller and less proliferative
hematopoietic clusters in the dorsal aorta and in the yolk sac. Already at E10.5,
homozygous Steel mutants show a reduction in pre-HSC numbers, yolk sac
erythropoiesis, and fetal liver cellularity. At E11.5 these mutants display
decreased progenitor numbers in all hematopoietic sites. 
Summary and Conclusions: Our data suggest that, contrary to earlier reports,
Kit signalling plays a role in early pre-liver hematopoiesis. In addition, our data
identified a previously unrecognized role for KitL in the maturation and/or expan-
sion of hematopoietic progenitors originating from the yolk sac, that could con-
tribute to the anaemia observed later in development. Ongoing studies aim at
elucidating the mechanism by which KitL exerts its role in early hematopoiesis.
Red blood cells and iron - Biology
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DEREGULATION OF GENES RELATED TO IRON AND MITOCHONDRIAL
METABOLISM IN REFRACTORY ANEMIA WITH RING SIDEROBLASTS
M. Del Rey1,2,* R. Benito1,2, C. Fontanillo1,2, F.J. Campos-Laborie1.2,
K. Janusz1,2, M. Abáigar1,2, M. Hernández-Sánchez1,2, R. Cuello3,
D. Borrego3, J. De Las Rivas1,2, K.I. Mills4, J.M. Hernández-Rivas1,2,5
1IBMCC, Centro de Investigación del Cáncer (CIC), Universidad de Salaman-
ca-CSIC, 2IBSAL, Instituto de Investigación Biomédica de Salamanca, Sala-
manca, 3Servicio de Hematología, Hospital Clínico de Valladolid, Valladolid,
Spain, 4Centre for Cancer Research and Cell Biology, Queen’s University
Belfast, Belfast, United Kingdom, 5Servicio de Hematología, Hospital Univer-
sitario de Salamanca, Salamanca, Spain
Background: The presence of SF3B1 gene mutations is a hallmark of
Myelodysplastic Syndrome with ring sideroblasts (MDS-RS) and could be relat-
ed to the iron accumulation in these patients. However, the mechanisms under-
lying that characterize the MDS-RS are not completely understood.
Aims: In order to gain insight in the molecular basis of MDS-RS, an integrative
study of the expression and mutational status of genesrelated to iron andmito-
chondrial metabolism was carried out.
Methods: A total of 231 low-risk MDS patients (50,3% MDS-RS, 49,7% refrac-
tory cytopenia with unilineage dysplasia patients-RCUD) and 81 controls were
studied. The gene expression profile was analysed using the Human Genome
Expression Array (U133 Plus 2.0) from Affymetrix. Array-based sequence cap-
ture (Roche NimbleGen) followed by next-generation sequencing (Roche GS
FLX Titanium sequencing platform) was used to analyze 39 genes related to
iron and mitochondrial metabolism. The genes were selected according to our
previous gene expression data. Spliceosome-related genes were studied using
an amplicon sequencing design in GS Junior Instrument (Roche Applied Sci-
ence). In addition, Sanger sequencing was carried out.
Results: Patients with refractory anemia with ring sideroblasts (RARS) showed
a differential expression of 1145 genes compared to controls. Interestingly, 38%
(266 genes) of the over-expressed genes were related to iron and mitochondrial
metabolism. The comparison between RARS and RCUD patients showed a set
of 192 differentially expressed genes: 33% (42 genes) of the over-expressed
genes were also related to iron and mitochondrial metabolism. ALAD and mito-
chondrial transporters SLC25 (SLC25A37 and SLC25A38) genes were over-
expressed in RARS. Most of the MDS-RS patients (94,3%) carried mutations in
any spliceosome-related gene. In addition, our analysis of the ALAD gene iden-
tified two polymorphisms (rs8177807 and rs2228083) in exon 6 and located 49
bases from each other. The occurrence of both polymorphisms (“variant haplo-
type”) was more frequent in MDS-RS (12%) than in members of the other groups
analyzed (5%). (p=0.07). Furthermore, an un-described variant in the exon 7
was found in the ALAD gene in one RARS patient with a mutation in SF3B1.
The positively charged arginine residue (R174) was replaced by an uncharged
cysteine residue. The three-dimensional structure showed that R174 residue is
completely buried into the monomeric structure and the protein was predicted
to be potentially damaging. The variant was not found in any of the control sam-
ples or in those analyzed from RCUD patients. An over-expressed gene-signa-
ture of 71 genes was identified between patients with SF3B1 mutations and
patients without the mutations. Interestingly, GDF15 was overexpressed in
patients showing SF3B1 mutations. In addition, other genes such as PPP2R5B,
PPP1R16A and DDIT4L, related to SF3B1 and GDF15, were up-regulated in
the mutated group. A functional analysis with this gene set showed two dereg-
ulated pathways: porphyrin biosynthesis and heme biosynthesis (p<0.001).
Summary and Conclusions: The deregulation of genes involved in iron and
mitochondrial metabolism provides new insights in our knowledge of MDS-RS.
Our study revealed mutations in spliceosome-related genes in almost 100% of
the MDS-RS. The presence of variations identified in ALAD gene could have
a possible role in the predisposition to disease (as a first event) as well as con-
tributing to the pathogenesis of MDS-RS where spliceosome-related genes
mutations could be the trigger cause.
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THE PRESENCE OF HEMOGLOBIN S IS ASSOCIATED WITH MIRNA
DEREGULATION IN CD34+-DERIVED ERYTHROID CELLS
T.A. Fornari1,* C. Lanaro1, K.Y. Fertrin1, N. Conran1, S.T. O Saad1, F.F. Costa1
1Hematology and Hemotherapy Center, State University of Campinas, Camp-
inas, Brazil
Background: Sickle cell disease (SCD) is a recessive genetic abnormality-
caused by a point mutation of the HBB gene (Glu6Val) that results in thepro-
duction of hemoglobin S (HbS), leading to chronic hemolysis andvaso-occlu-
sion. In addition to its ability to polymerize under hypoxicconditions, HbS may
give rise to increased oxidative stress caused by freeheme and iron secondary
to its intrinsic instability. MicroRNAs (miRNAs) canmodulate post-transcriptional
erythroid-specific regulators.
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Aims: The aim of thisstudy was to investigate miRNA expression profiles and
the possiblepost-transcriptional role of these molecules associated with the
presence ofHbS in sickle cell trait and in compound heterozygosity for HbS
and δβ-thalassaemiaSicilian type.
Methods: We obtained samples from individuals from the same family with
sickle cell trait (βS/βA),two sickle-δβ-thalassaemia Sicilian type patients (βS/βδβ),
two δβ-thalassaemia Sicilian type heterozygotes(βδβ/βA) and normal control
(βA/βA).CD34+-derived erythroid cells werecultured for 13 days and used to
determine the miRNA expression profile.miRNAs were hybridized using an Agi-
lent miRNA microarray platform and theprofiles were subjected to bioinformatics
data analysis using GeneSpringsoftware (v11.0). Different databases, such as
miRBase (Release 21),TargetScan (Release 6.2) and microRNA.org (Release
2010) were used todetermine the predicted targets of miRNAs. The RNAhybrid
tool (BiBiServ) wasused to find the minimum free energy hybridization of each
miRNA and apossible target gene.
Results: Twenty five miRNAs were up-regulated inβS/βδβ and in βS/βA com-
pared to βA/βA and βδβ/βA. In silico analysis showedthat eight miRNAs target
genes involved in cellular adhesion (CD36, ICAM4,and ITGB1), antioxidant
defense mechanisms (CAT, catalase), and hemoglobinaffinity for oxygen
(BPGM and MINPP1, 2,3-bisphosphoglycerate mutase andphosphatase,
respectively). CD36, ICAM4, and ITGB1 are possible targets ofthe miR-17, 20a
and 20b and the latter is additionally targeted by miR-29b,29c and 30e. The
CAT gene is also targeted by miR-30e as well as by miR-148aand 148b. BPGM
is targeted by miRs 20a and 20b, while MINPP1 is onlytargeted by miR-30e.
We also found hemopexin (HPX), a major heme-bindingprotein, is a possible
target of miR-26b.
Summary and Conclusions: Our data suggest that,in an in vitro model, the
presence of HbS is associated with miRNAderegulation that may be associated
to pathologic processes found ex vivo in reticulocytes and mature erythrocytes
from SCD patients. Financial supportby FAPESP and CNPq/INCTS.
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ORAL IRON SUPPLEMENTS INCREASE HEPCIDING AND DECREASE
ABSORPTION FROM DAILY OR TWICE DAILY DOSES: STUDIES WITH
STABLE IRON ISTOPIC LABELS IN YOUNG WOMEN
D. Moretti1,* J. Goede2, C. Zeder3, T. Harold4, M. Alida5, B. Gary6, S. Dorine7,
Z. Michael1
1Laboratory of Human Nutrition, ETH Zürich, 2Hematology, Unioversity Hospital
Zürich, 3ETh Zürich, Zürich, Switzerland, 4Radboud University Medical Centre,
Nijmegen, 5Wageningen University, Wageningen, Netherlands, 6College of
Physicians and Surgeons, Columbia University, New York, United States, 7Lab-
oratory Medicine, Translational Metabolic Laboratory, Radboud University Med-
ical Centre, Nijmegen, Netherlands
Background: Oral iron supplementation is used to treat iron deficiency, but
absorption is often low and correction is variable.
Aims: Determine the duration and magnitude of the plasma hepcidin (pHep)
response induced by oral iron (Fe) supplements and concomitantly measure
bioavailability in healthy iron depleted young women.
Methods: After randomization of 42 subjects with plasma ferritin<20 µg/L, pHep
(measured by C-ELISA), iron status and inflammation markers were monitored
at regular intervals. On day 1, no supplements were given (control day). On
days 2 and 3, subjects received iron supplements containing 40, 60, 80, 160
or 240 mg Fe as FeSO4 as either single or two consecutive daily doses extrin-
sically labeled with stable iron isotopes 54FeSO4, 57FeSO4 or 58FeSO4. Iron
bioavailability was measured by assessing the isotopic enrichment of erythro-
cytic iron 14 days after administration.
Results: Both Fe dose (P<0.05) and time of day (P<0.05) were associated
with increase in pHep. Compared to control days, pHep was significantly higher
at 8h and 24h after administration for 60, 80, 160 and 240 mg (P<0.05) but not
for 40 mg Fe. Total Fe absorption from the Fe dose on the second day of the
consecutive administration compared to a single Fe dose on the first day was
not significantly decreased for 40 mg, but was decreased by 37% for 80 mg,
31% for 160 mg and 45% for 240 mg (for all, P<0.01). Fractional absorption
was highest from the 40 mg dose. With twice per day dosing (60 mg Fe) the
afternoon dose was less bioavailable (P<0.05).
Summary and Conclusions: In Fe-depleted women, consecutive day doses
of supplemental Fe at 60 mg or above increase pHep and decrease fractional
Fe bioavailability, while a dose of 40 mg does not. These important new data
will help guide optimal dosing regimens for Fe supplements in women.
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RED BLOOD CELL GLYCOLYTIC INHIBITION ALTERS INTRACELLULAR
ION CONCENTRATIONS, LEADS TO DECREASED DEFORMABILITY, AND
UPREGULATES EXPRESSION OF CLEARANCE SIGNALS
R. Huisjes1,* L. Verhagen1, B. van Oirschot1, W. van Solinge1, R. Schiffelers1,
R. van Wijk1
1Department of Clinical Chemistry and Haematology, UMC Utrecht, Utrecht,
Netherlands
Background: enzymopathies is group of metabolic disorders of the erythrocyte
that leads to decreased intracellular energy production. Energy deprivation ulti-
mately results in premature clearance from the circulation in the spleen
(extravascular hemolysis). The precise mechanism by which energy-deprived
cells are recognized and cleared is largely unknown. One candidate mechanism
could involve disturbed ion balance due to defective function of ATP-dependent
ion channels in the red cell membrane, with consequent expression of clearance
signals, and loss of red blood cell deformability.
Aims: To investigate the effect of energy-depletion on ion channel function,
the exposure of clearance signals on the surface of the red cell, and red blood
cell deformability in a model for energy-depleted red blood cells.
Methods: Isolated erythrocytes were resuspended in HEPES buffered Ringers
solution (pH=7.4) and incubated overnight at 37ºC with 1mM D-glucose and
various concentrations (5-10mM) of 2-deoxy-D-glucose. 2-deoxy-D-glucose
(2dDg) is a glycolytic inhibitor acting on hexokinase, thereby serving as a model
for energy-depleted red blood cells. Intracellular calcium was analysed by flow
cytometry with fluo-4 AM as a fluorescent calcium probe and intracellular sodium
and potassium concentrations were measured by flame photometry. ATP was
measured using the CellTiter-Glo Luminescent Cell Viability Assay. Deforma-
bility of erythrocytes was measured using osmotic gradient ektacytometry by
LoRRca. Expression of phosphatidylserine (Annexin-V) and CD47 on the ery-
throcyte membrane was examined by FACS.
Results: Upon incubation with various concentrations of 2-deoxy-D-glucose
(2dDg) sodium levels (39 mM vs control 8 mM) were increased in a dose-
dependent manner. Potassium (51 mM versus control 82 mM) and ATP con-
centrations (23 nM versus 7 nM) were decreased following treatment with 2dDg.
FACS analysis revealed increased intracellular concentration of calcium and
increased expression of CD47 and phosphatidylserine after incubation with
2dDg. Osmotic gradient ektacytometry showed decreased deformability after
incubation with 2dDg, reflected by a decreased EImax (maximal Elongation
Index, Figure). When compared with ektacytometry curves from a patient with
either hexokinase or pyruvate kinase deficiency, similar curves were obtained.
Importantly, osmotic gradient ektacytometry curves of erythrocytes incubated
with 2dDg are comparable (Figure).
Figure 1.
Summary and Conclusions: Glycolytic inhibition alters intracellular red blood
cell ion concentrations, and causes decreased deformability of erythrocytes.
The decreased deformability as seen in 2dDg-incubated erythrocytes is com-
parable with the decreased deformability seen in patients with hexokinase and
pyruvate kinase deficiency. Moreover, glycolytic inhibition is associated with
upregulation of removal signals CD47 and phosphatidyl serine on the erythro-
cyte membrane. Loss of deformability and upregulation of removal signals in
energy-deprived red blood cells may play a role in the premature removal of
erythrocytes in red blood cell enzymopathies.
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MODIFIED ACTRIIB-MFC FUSION PROTEIN (RAP-536) INCREASES
FUNCTIONAL RED BLOOD CELLS AND IMPROVES SICKLE CELL
DISEASE PATHOLOGY WITH OR WITHOUT HYRDOXYUREA IN A MURINE
MODEL
R.N. Suragani1,* R. Li1, S. Cawley1, S. Pearsall1, R. Kumar1
1ACCELERON PHARMA, Cambridge, United States
Background: Sickle cell disease (SCD) is characterized by the presence of
the sickle hemoglobin variant (HbS) of the b-globin gene. Under hypoxic con-
ditions, HbS polymerizes, causing irreversibly sickled red blood cells (RBC).
Manifestations of SCD include increased reticulocytes, splenomegaly, impaired
blood flow due to intravascular sickling, and vaso-occlusive crises. The only
approved therapy for SCD is hydroxyurea (HU), which decreases irreversibly
sickled cells and painful events.. However, myelosuppression is a dose limiting
toxicity and ~1/3 of patients do not respond to HU therapy, thereby highlighting
the need for alternative treatment strategies
Aims: Luspatercept (ACE-536) is a modified type IIB activin receptor-Fc fusion
protein1 which acts as a ligand trap for members of the TGF-b superfamily to
promote late-stage erythroid differentiation. In a murine model of b-thalassemia,
RAP-536 (murine ortholog of ACE-536) corrected anemia and mitigated disease
complications of b-thalassemia2. In this study, we evaluated RAP-536 as a
monotherapy and in combination with HU in a murine model of SCD
Methods: SCD mice3 (βS/βS, 6 and 12 weeks old) were dosed with RAP-536
(10 mg/kg, twice weekly SC) or TBS (VEH) control (N=4-6/group). Combination
treatment with HU (100 mg/kg, i.p.) and RAP-536 (10 mg/kg SC) twice weekly
for 3 months was compared with vehicle or HU monotherapy. Non-symptomatic
compound heterozygote (β/βS) littermates were used as controls (N=5/group).
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